- Moderna's short interest surged to 14.58% in March, signaling investor caution.
- Analysts forecast an average price target of $50.96, offering significant potential upside.
- GuruFocus estimates a GF Value of $21.62, indicating a potential downside risk.
In March, Moderna (MRNA) experienced a notable increase in short interest among healthcare stocks, climbing to 14.58% from February's 13.19%. This uptick reflects growing investor scrutiny as the biotechnology firm, renowned for its focus on mRNA therapeutics and vaccines, navigates potential regulatory shifts. The heightened attention has contributed to its current Strong Sell rating.
Wall Street Analysts Forecast and Insights
According to insights from 21 analysts, the one-year price targets for Moderna Inc (MRNA) present an average target price of $50.96. This range includes a high estimate of $212.00 and a low estimate of $25.00, suggesting a significant potential upside of 104.32% from its current price of $24.94. For a deeper dive into these projections, explore the Moderna Inc (MRNA, Financial) Forecast page.
Furthermore, the consensus recommendation from 27 brokerage firms positions Moderna Inc's (MRNA, Financial) average brokerage recommendation at 3.0, which corresponds to a "Hold" status. It's important to note that this rating scale ranges from 1 to 5, where 1 signifies a Strong Buy, and 5 indicates a Sell.
GuruFocus' Valuation Perspective
Utilizing GuruFocus estimates, the projected GF Value for Moderna Inc (MRNA, Financial) over the coming year stands at $21.62. This estimation suggests a potential downside of 13.31% from its current price of $24.94. The GF Value is derived from historical trading multiples and considers both past business growth and future performance estimates. For further analysis, visit the Moderna Inc (MRNA) Summary page.
